Clinical Trial Update: A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer. [Phase 2]

View source ↗

Summary

This Phase I-II trial evaluates the safety and preliminary efficacy of AB122 (PD-1 antagonist) and AB928 (adenosine receptor antagonist) in combination with che…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• AB122
• AB928

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Rectal Cancer | Phase 2 | Status: RECRUITING